InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
Product | Citation | Year | Journal | Authors | Page |
---|---|---|---|---|---|
Pam3CSK4 | Inflammasome-induced extracellular vesicles harbour distinct RNA signatures a... | 2021 | J Extracell Vesicles | Budden C.F. et al. | DOI: 10.1002/jev2.12127 |
Alhydrogel® adjuvant 2% | Development of a novel ZIKV vaccine comprised of immunodominant CD4+ and CD8+... | 2021 | Vaccine | Sun J. et al. | OI: 10.1016/j.vaccine.2021.07.036 |
Adju-Phos® adjuvant | Development of combination adjuvant for efficient T cell and antibody respons... | 2021 | PLoS One. | Haseda Y. et al. | DOI: 10.1371/journal.pone.0254628 |
Alhydrogel® adjuvant 2% | Development of combination adjuvant for efficient T cell and antibody respons... | 2021 | PLoS One. | Haseda Y. et al. | DOI: 10.1371/journal.pone.0254628 |
EIF2AK2 | Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote vir... | 2021 | Cell Rep. | Zaman A. et al. | DOI: 10.1016/j.celrep.2021.109491 |
Poly(I:C) LMW | Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote vir... | 2021 | Cell Rep. | Zaman A. et al. | DOI: 10.1016/j.celrep.2021.109491 |
TLR-Related Dominant Negative Genes | Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote vir... | 2021 | Cell Rep. | Zaman A. et al. | DOI: 10.1016/j.celrep.2021.109491 |
J774-Dual™ Cells | High potency STING agonists engage unique myeloid pathways to reverse pancrea... | 2021 | J Immunother Cancer. | Ager C.R. et al. | DOI: 10.1136/jitc-2021-003246 |
THP1-Dual™ Cells | High potency STING agonists engage unique myeloid pathways to reverse pancrea... | 2021 | J Immunother Cancer. | Ager C.R. et al. | DOI: 10.1136/jitc-2021-003246 |
IFA | Antigenic and immunogenic evaluation of permutations of soluble hepatitis C v... | 2021 | PLoS One. | Prentoe J. et al. | DOI: 10.1371/journal.pone.0255336 |
AddaVax™ | Antigenic and immunogenic evaluation of permutations of soluble hepatitis C v... | 2021 | PLoS One. | Prentoe J. et al. | DOI: 10.1371/journal.pone.0255336 |
Poly(I:C) HMW | FIP200 restricts RNA virus infection by facilitating RIG-I activation. | 2021 | Commun Biol. | Wang L. et al. | DOI: 10.1038/s42003-021-02450-1 |
Poly(A:U) | FIP200 restricts RNA virus infection by facilitating RIG-I activation. | 2021 | Commun Biol. | Wang L. et al. | DOI: 10.1038/s42003-021-02450-1 |
Poly(I:C) LMW | FIP200 restricts RNA virus infection by facilitating RIG-I activation. | 2021 | Commun Biol. | Wang L. et al. | DOI: 10.1038/s42003-021-02450-1 |
LPS-B5 (LPS from E. coli O55:B5) | FIP200 restricts RNA virus infection by facilitating RIG-I activation. | 2021 | Commun Biol. | Wang L. et al. | DOI: 10.1038/s42003-021-02450-1 |
Poly(dG:dC) | FIP200 restricts RNA virus infection by facilitating RIG-I activation. | 2021 | Commun Biol. | Wang L. et al. | DOI: 10.1038/s42003-021-02450-1 |
Poly(dA:dT) | FIP200 restricts RNA virus infection by facilitating RIG-I activation. | 2021 | Commun Biol. | Wang L. et al. | DOI: 10.1038/s42003-021-02450-1 |
5'ppp-dsRNA | FIP200 restricts RNA virus infection by facilitating RIG-I activation. | 2021 | Commun Biol. | Wang L. et al. | DOI: 10.1038/s42003-021-02450-1 |
R848 (Resiquimod) | Effective Cytotoxicity of Dendritic Cells against Established T Cell Lymphoma... | 2021 | J Immunol. | Dubois S. et al. | DOI: 10.4049/jimmunol.2001123 |
ODN 1585 - TLR9 ligand | Effective Cytotoxicity of Dendritic Cells against Established T Cell Lymphoma... | 2021 | J Immunol. | Dubois S. et al. | DOI: 10.4049/jimmunol.2001123 |